Go ad-free with Coinranking Elite. Go ad-free with Elite. No ads. Full Pro Chart. All premium features. No ads. Full Pro Chart.

What is EncrypGen (DNA)?

Quick Facts

  • Token symbol: DNA
  • Token standard: ERC-20 on Ethereum
  • Founded: 2017, United States
  • Platform launched: 2018
  • Core platform: Gene-Chain
  • Sector: Genomics, healthcare, blockchain
  • Founders: Dr. David Koepsel and Dr. Vanessa Gonzalez Covarrubias

Introduction

EncrypGen is a blockchain-based platform designed to give individuals full control over their genomic data. Using its native DNA token, the platform connects data donors with scientific researchers in a privacy-preserving, peer-to-peer marketplace.

The project sits at the intersection of biotechnology and decentralized technology, tackling a growing challenge: who owns and profits from genetic data?

History & Background

EncrypGen was incorporated in the United States in 2017. Its core product, Gene-Chain, was launched in 2018 as a specialized blockchain solution tailored to the unique needs of genomic data management.

The founding team recognized that large DNA testing companies were profiting from customer data, often without meaningful consent or compensation to donors. EncrypGen was built to address this imbalance directly.

How EncrypGen Works

The Gene-Chain platform allows individuals to upload their raw DNA data files. The platform de-identifies this data by stripping out personally identifiable information such as names and email addresses, protecting user privacy.

Researchers and institutions can then browse Gene-Chain profiles, search for data that matches their study requirements, and purchase access using DNA tokens. This creates a transparent, auditable, and peer-to-peer data marketplace on the blockchain.

Tokenomics

The DNA token serves as the sole medium of exchange on the Gene-Chain platform. It is an ERC-20 token on the Ethereum blockchain.

Tokens flow from data buyers (researchers) to data sellers (individual donors), aligning incentives so that the people who generate genetic data are directly rewarded for contributing to science and medicine.

Circulating Supply ? 70.94 million DNA
Total supply ? 70.94 million DNA
Max supply ? -- DNA
Updated 4d ago

Ecosystem & Use Cases

EncrypGen targets two key groups:

  • Data donors — patients and individuals who want to monetize or contribute their genetic data.
  • Researchers — scientists, pharmaceutical companies, and institutions seeking access to diverse genomic datasets.

The Gene-Chain platform offers a distributed, searchable genomic database that is designed to be more secure and privacy-respecting than traditional cloud-based repositories.

Team, Governance & Community

EncrypGen was co-founded by Dr. David Koepsel, an ethicist, attorney, and author specializing in genetics and data ownership, and Dr. Vanessa Gonzalez Covarrubias, a pharmacogenomic research scientist. This combination of legal, ethical, and scientific expertise shaped the project's design philosophy.

The project was headquartered in Coral Springs, Florida, USA.

Advantages

  • Data sovereignty — individuals retain ownership and control over their genetic information.
  • Privacy by design — de-identification processes protect user identities before data is shared.
  • Direct compensation — donors are rewarded in DNA tokens for contributing to research.
  • Transparent transactions — blockchain creates an immutable and auditable record of data access.

Risks & Challenges

  • Project activity — reports indicate the platform and website have been inactive, raising concerns about long-term viability.
  • Regulatory complexity — genomic data is subject to strict health and privacy regulations across jurisdictions.
  • Adoption barrier — convincing both research institutions and individual donors to use a new platform is a significant hurdle.
  • Data sensitivity — despite de-identification, genomic data carries inherent re-identification risks.

Long-Term Vision

EncrypGen envisioned a world where individuals — not corporations — profit from the value of their own genetic information. By combining blockchain transparency with genomic science, the project aimed to reshape how humanity shares biological data for medical advancement.

The broader concept of decentralized genomic data marketplaces remains a compelling idea in the DeSci (Decentralized Science) space, regardless of the project's current operational status.

Frequently Asked Questions

EncrypGen is a blockchain platform that allows individuals to store their genomic data and sell access to it to researchers. Transactions on the platform are conducted using the native DNA token.

DNA is the native ERC-20 utility token of the EncrypGen platform. It serves as the medium of exchange between genomic data sellers and buyers on the Gene-Chain marketplace.

Gene-Chain is EncrypGen's proprietary blockchain platform built specifically for genomic data. It enables the searching, storing, sharing, buying, and selling of de-identified genetic data.

The platform de-identifies raw DNA data files by removing personal details like names and email addresses before they are made available to researchers. This helps protect donor identity while preserving the scientific utility of the data.

EncrypGen was co-founded by Dr. David Koepsel, an ethicist and attorney, and Dr. Vanessa Gonzalez Covarrubias, a pharmacogenomic research scientist. The company was registered in the United States in 2017.

The DNA token is an ERC-20 token issued on the Ethereum blockchain. Its contract address is publicly verifiable on-chain.

Large DNA testing companies have historically profited from customer genetic data without adequately compensating or informing donors. EncrypGen was designed to return control and economic benefit to the individuals who generate that data.

Reports from 2026 indicate that the EncrypGen website is unresponsive and the associated Florida LLC is listed as inactive, suggesting the project is no longer in active operation.